Skip to main content
NIH funding notice PAR-23-214

Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)

Closed on October 4, 2023.

Posted
June 6, 2023
Close date
October 4, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,067,207 in first-year total cost, median $533,604.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1-AN-Z(55)]1
  2. Special Emphasis Panel[ZRG1-BN-M(91)]1

Most frequent institutions

  1. LOUISIANA STATE UNIV HSC SHREVEPORT1
  2. UNIVERSITY OF ILLINOIS AT CHICAGO1
Competing awards under PAR-23-214 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024Impact of SARS-CoV-2 on the cerebrovasculature as a risk factor for VCID: Role of Wnt/beta-catenin1R56NS138437-01LUTZ, SARAH ELIZABETHUNIVERSITY OF ILLINOIS AT CHICAGO, IL$561,155ZRG1
2024Mechanistic Investigation of Neuropathological Interactions between COVID-19 and Progression of Lewy Pathology and Dementia1R56NS138538-01LU, XIAOHONGLOUISIANA STATE UNIV HSC SHREVEPORT, LA$506,052ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-23-214: Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed) | ScienceDex | ConductScience